RenovoCath®: Intra-arterial catheter delivery of chemotherapy agents for the collection of real-world data.
Study summary
This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to solid tumors using the RenovoCath® catheter.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Eligibility Criteria:
1. Male and female patients who have been diagnosed with solid tumor cancers and are at least 18 years of age at the time of the first IA procedure
2. Patients willing to provide informed consent and HIPAA release for use of their relevant medical records
Primary outcome measure(s)
Safety of RenovoCath® as assessed by the number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath. — From the time of the first treatment, until 30 days after the last treatment Number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath.
Performance of RenovoCath® as assessed by the number of participants experiencing adverse events related to the inter-arterial drug delivery procedure. — From the time of the first treatment, until 30 days after the last treatment Track the performance of RenovoCath® in a real-world setting delivering a variety of therapeutic agents
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.